Recently Added Drugs
1. Akeega patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383543 | JANSSEN BIOTECH | NA |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
2. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12396986 | GLAXOSMITHKLINE | NA |
Nov, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
3. Arynta patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433859 | AZURITY | NA |
Apr, 2040
(14 years from now) | |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 16 June, 2025
Treatment: Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd)
Dosage: SOLUTION
More Information on Dosage
ARYNTA family patents
4. Aurlumyn patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409184 | BTG INTL | NA |
Aug, 2041
(15 years from now) | |
| US12409183 | BTG INTL | NA |
Jul, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-465) | Feb 13, 2031 |
Drugs and Companies using ILOPROST ingredient
Market Authorisation Date: 13 February, 2024
Treatment: Treatment of severe frostbite in adults to reduce the risk of digit amputations
Dosage: SOLUTION
More Information on Dosage
AURLUMYN family patents
5. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409176 | INTRA-CELLULAR | NA |
Mar, 2039
(13 years from now) | |
| US12410195 | INTRA-CELLULAR | NA |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of depressive episodes associated with bipolar disorder
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
6. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403099 | IMPAX | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
7. Cuvrior patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12358861 | ORPHALAN | NA |
May, 2039
(13 years from now) | |
| US12358862 | ORPHALAN | NA |
May, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2025 |
| Orphan Drug Exclusivity(ODE-401) | Apr 28, 2029 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson's disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET
How can I launch a generic of CUVRIOR before it's drug patent expiration?
More Information on Dosage
CUVRIOR family patents
8. Danziten patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403140 | AZURITY | NA |
Feb, 2040
(14 years from now) | |
Drugs and Companies using NILOTINIB TARTRATE ingredient
Market Authorisation Date: 07 November, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
DANZITEN family patents
9. Dawnzera (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127276 | IONIS PHARMS INC | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | |
| US9181549 | IONIS PHARMS INC | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | |
| US9670492 | IONIS PHARMS INC | NA |
Aug, 2034
(8 years from now) | |
| US10294477 | IONIS PHARMS INC | NA |
May, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9315811 | IONIS PHARMS INC | NA |
Oct, 2032
(7 years from now) | |
Drugs and Companies using DONIDALORSEN SODIUM ingredient
Market Authorisation Date: 21 August, 2025
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older
Dosage: SOLUTION
More Information on Dosage
DAWNZERA (AUTOINJECTOR) family patents
10. Eligard Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12397120 | TOLMAR | NA |
Dec, 2041
(16 years from now) | |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 23 January, 2002
Treatment: Treatment of advanced prostatic cancer
Dosage: POWDER
More Information on Dosage
ELIGARD KIT family patents
11. Enbumyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11123319 | CORSTASIS THERAP | NA |
Dec, 2040
(15 years from now) | |
Drugs and Companies using BUMETANIDE ingredient
Market Authorisation Date: 12 September, 2025
Treatment: NA
Dosage: SPRAY
More Information on Dosage
ENBUMYST family patents
12. Farxiga patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409186 | ASTRAZENECA AB | NA |
Apr, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Reducing the risk of sustained egfr decline, end-stage kidney disease, cv death, and hospitalization for heart failure in adults with ckd at risk of progression and without type ii diabetes after at l...
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
13. Fensolvi Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12397120 | TOLMAR | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-829) | May 01, 2023 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 01 May, 2020
Treatment: Treatment of pediatric patients with central precocious puberty
Dosage: POWDER
More Information on Dosage
FENSOLVI KIT family patents
14. Ibrance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE47739 (Pediatric) | PFIZER | NA |
Sep, 2027
(1 year, 10 months from now) | |
|
US10723730 (Pediatric) | PFIZER | NA |
Aug, 2034
(8 years from now) | |
|
US11065250 (Pediatric) | PFIZER | NA |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
| M(M-14) | Sep 16, 2028 |
| Pediatric Exclusivity(PED) | Mar 16, 2029 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 16 March, 2028
Market Authorisation Date: 03 February, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of IBRANCE before it's drug patent expiration?
More Information on Dosage
IBRANCE family patents
15. Inlexzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403086 | JANSSEN BIOTECH | NA |
Jun, 2030
(4 years from now) | |
| US8679094 | JANSSEN BIOTECH | NA |
Apr, 2032
(6 years from now) | |
| US10729823 | JANSSEN BIOTECH | NA |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 09, 2028 |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 September, 2025
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
INLEXZO family patents
16. Kabiven In Plastic Container patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390398 | FRESENIUS KABI USA | NA |
May, 2036
(10 years from now) | |
Market Authorisation Date: 25 August, 2014
Treatment: NA
Dosage: EMULSION
More Information on Dosage
KABIVEN IN PLASTIC CONTAINER family patents
17. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12419894 | NOVARTIS | NA |
Apr, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage
KISQALI family patents
18. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12419894 | NOVARTIS | NA |
Apr, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
19. Kloxxado patent expiration
Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12414915 | HIKMA | NA |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2024 |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 August, 2025
Treatment: NA
Dosage: SPRAY
How can I launch a generic of KLOXXADO before it's drug patent expiration?
More Information on Dosage
KLOXXADO family patents
20. Koselugo patent expiration
KOSELUGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(4 months from now) | |
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(4 months from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(1 year, 1 month from now) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
Market Authorisation Date: 10 September, 2025
Treatment: Treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: GRANULE
More Information on Dosage
KOSELUGO family patents
21. Kyxata patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427104 | AVYXA HOLDINGS | NA |
Apr, 2045
(19 years from now) | |
Drugs and Companies using CARBOPLATIN ingredient
Market Authorisation Date: 08 August, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
KYXATA family patents
22. Kyzatrex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403146 | MARIUS | NA |
Mar, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE
More Information on Dosage
KYZATREX family patents
23. Lutathera patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12415003 | AAA USA INC | NA |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
| New Patient Population(NPP) | Apr 23, 2027 |
| Orphan Drug Exclusivity(ODE-479) | Apr 23, 2031 |
| Pediatric Exclusivity(PED) | Oct 23, 2031 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 23 October, 2030
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (gep-nets), including foregut, midgut, and hindgut neuroen...
Dosage: SOLUTION
More Information on Dosage
LUTATHERA family patents
24. Lytgobi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(7 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833151 | TAIHO ONCOLOGY | Pharmaceutical composition including sodium alkyl sulfate |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| ODE*(ODE*) | Sep 30, 2029 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET
More Information on Dosage
LYTGOBI family patents
25. Micafungin In Sodium Chloride 0.9% patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403173 | BAXTER HLTHCARE CORP | NA |
Dec, 2037
(12 years from now) | |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 29 September, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
MICAFUNGIN IN SODIUM CHLORIDE 0.9% family patents
26. Ohtuvayre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409180 | VERONA PHARMA | NA |
Feb, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents
27. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10329260 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10689346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11230530 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11708333 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US12116346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10125102 (Pediatric) | BIOCRYST | NA |
Oct, 2035
(9 years from now) | |
|
US10662160 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11117867 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11618733 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12344585 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 03, 2028 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 04 June, 2027
Market Authorisation Date: 03 December, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ORLADEYO family patents
28. Otezla Xr patent expiration
OTEZLA XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(8 years from now) | |
| US11752129 | AMGEN INC | NA |
May, 2042
(16 years from now) | |
| US11969409 | AMGEN INC | NA |
May, 2042
(16 years from now) | |
Drugs and Companies using APREMILAST ingredient
Market Authorisation Date: 29 August, 2025
Treatment: Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of plaque psoriasis by administering apremilast with food
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OTEZLA XR family patents
29. Perikabiven In Plastic Container patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390398 | FRESENIUS KABI USA | NA |
May, 2036
(10 years from now) | |
Market Authorisation Date: 25 August, 2014
Treatment: NA
Dosage: EMULSION
More Information on Dosage
PERIKABIVEN IN PLASTIC CONTAINER family patents
30. Qbrelis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433931 | AZURITY | NA |
Nov, 2035
(10 years from now) | |
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: Treatment of hypertension
Dosage: SOLUTION
How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage
QBRELIS family patents
31. Rinvoq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12365689 | ABBVIE | NA |
Oct, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-946) | Apr 26, 2027 |
| New Patient Population(NPP) | Apr 26, 2027 |
| New Indication(I-966) | Apr 28, 2028 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RINVOQ family patents
32. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12398102 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
33. Sotalol Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403109 | ALTATHERA PHARMS LLC | NA |
Aug, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 02, 2016 |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.
Dosage: SOLUTION
More Information on Dosage
SOTALOL HYDROCHLORIDE family patents
34. Subvenite patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596634 | OWP PHARMS | NA |
May, 2040
(14 years from now) | |
| US11612566 | OWP PHARMS | NA |
May, 2040
(14 years from now) | |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 16 September, 2025
Treatment: Conversion to monotherapy for partial-onset seizures in patients 16 years and older
Dosage: SUSPENSION
More Information on Dosage
SUBVENITE family patents
35. Tezruly patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12427108 | NOVITIUM PHARMA | NA |
Feb, 2041
(15 years from now) | |
Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 July, 2024
Treatment: Treatment of symptomatic benign prostatic hyperplasia (bph) in patients who are in need of a liquid composition of terazosin
Dosage: SOLUTION
More Information on Dosage
TEZRULY family patents
36. Tonmya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117936 | TONIX | NA |
Mar, 2034
(8 years from now) | |
| US10864175 | TONIX | NA |
Mar, 2034
(8 years from now) | |
| US9636408 | TONIX | NA |
Mar, 2034
(8 years from now) | |
| US9956188 | TONIX | NA |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2028 |
Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 August, 2025
Treatment: NA
Dosage: TABLET
More Information on Dosage
TONMYA family patents
37. Trelegy Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12396986 | GLAXOSMITHKLINE | NA |
Nov, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
TRELEGY ELLIPTA family patents
38. Vizz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12414942 | LENZ THERAP | NA |
Mar, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Treatment: Treatment of presbyopia
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
39. Vykat Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12419895 | SOLENO THERAP | NA |
Nov, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 26, 2028 |
Drugs and Companies using DIAZOXIDE CHOLINE ingredient
Market Authorisation Date: 26 March, 2025
Treatment: Treating hyperphagia and reducing food-related behaviors in prader-willi syndrome patients
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VYKAT XR family patents
40. Wayrilz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9580427 | GENZYME CORP | NA |
Mar, 2033
(7 years from now) | |
| US8940744 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US9266895 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US9994576 | GENZYME CORP | NA |
Sep, 2033
(7 years from now) | |
| US11708370 | GENZYME CORP | NA |
Feb, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178818 | GENZYME CORP | NA |
Oct, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2030 |
Drugs and Companies using RILZABRUTINIB ingredient
NCE-1 date: 29 August, 2029
Market Authorisation Date: 29 August, 2025
Treatment: Method for treating adult patients with persistent or chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment, by achieving a platelet count of at least 50,...
Dosage: TABLET
More Information on Dosage
WAYRILZ family patents
41. Xatmep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12396947 | AZURITY | NA |
Jan, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-137) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-138) | Apr 25, 2024 |
Drugs and Companies using METHOTREXATE SODIUM ingredient
Market Authorisation Date: 25 April, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XATMEP family patents
42. Xromi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12409156 | NOVA LABS LTD | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 04, 2027 |
| Orphan Drug Exclusivity(ODE-470) | Apr 04, 2031 |
Drugs and Companies using HYDROXYUREA ingredient
Market Authorisation Date: 04 April, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XROMI family patents
43. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390453 | ARCUTIS | NA |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Jul 09, 2027 |
| New Indication(I-969) | May 22, 2028 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 15 December, 2023
Treatment: NA
Dosage: FOAM
More Information on Dosage
ZORYVE family patents